SynthesisJACC. Cardiovascular interventions2024
Outcomes With Limus- vs Paclitaxel-Coated Balloons for Percutaneous Coronary Intervention: Meta-Analysis of Randomized Controlled Trials.
Synthesis in JACC. Cardiovascular interventions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Drug-coated balloons in coronary in-stent restenosis: a systematic review and meta-analysis comparing sirolimus and biolimus with paclitaxel platforms.Cardiovascular intervention and therapeutics · 2026Pooled it
- A meta-analysis of the efficacy of limus-coated balloons vs. paclitaxel-coated balloons for coronary artery disease.Frontiers in cardiovascular medicine · 2026Pooled it
- Drug-Coated Balloons Versus Other Percutaneous Coronary Intervention Strategies in De Novo Coronary Artery Disease: A Systematic Review, Meta-Analysis With Trial Sequential Analysis.Cardiovascular therapeutics · 2026Pooled it
- Paclitaxel-Coated Balloons versus Drug-Eluting Stents in Small Vessel Coronary Artery Disease: A Systematic Review and Meta-Analysis.Arquivos brasileiros de cardiologia · 2025Pooled it
- Arterial remodeling and plaque changes after balloon angioplasty for de novo coronary lesions using DCB.Cardiovascular intervention and therapeutics · 2026Article
- Subgroup variations in effectiveness of femoropopliteal sirolimus versus paclitaxel-coated balloon angioplasty: post hoc results of the randomised SIRONA trial.CVIR endovascular · 2026Article
- Performance of a sirolimus-eluting balloon with phospholipid nanocarriers in the treatment of long de novo coronary artery disease: the prospective GINGER trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- SirolimusWorld journal of methodology · 2026Article
- Head-to-head comparison of limus- versus paclitaxel-coated balloons in the treatment of in-stent restenosis: a meta-analysis.AsiaIntervention · 2026Article
- Paclitaxel-coated balloon with urea or iopromide as the excipient for treatment of coronary artery disease.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Blended Coronary Revascularization with Drug-Coated Balloon and Drug-Eluting Stent: A Narrative Review on Rationale, Clinical Evidence, and Future Perspectives.Journal of clinical medicine · 2025Review
- Drug-coated balloon angioplasty for chronic total coronary occlusions. Blended strategies: the best of two worlds.International journal of cardiology. Heart & vasculature · 2025Article
- Pantera Lux Drug-Coated Balloon for the Treatment of Coronary Artery Lesions in Routine Practice.Journal of clinical medicine · 2025Article
- From Mechanisms to Management: Tackling In-Stent Restenosis in the Drug-Eluting Stent Era.Current cardiology reports · 2025Review
- Drug-coated balloons in percutaneous coronary interventions: existing evidence and emerging hopes.Cardiology journal · 2025Review
- Research status and trends of drug-coated balloons in coronary artery disease: a bibliometric analysis.Frontiers in medicine · 2025Article
- Superiority of coronary paclitaxel DCBs to limus DCBs in the late angiographic outcomes: the first meta-analysis showing the differences of coronary DCBs.Cardiovascular diagnosis and therapy · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRandomized controlled trials (RCTs) examining the outcomes with limus drug-coated balloons (DCBs) vs paclitaxel DCBs were small and underpowered for clinical endpoints.
objectivesThis study sought to compare the angiographic and clinical outcomes with limus DCBs vs paclitaxel DCBs for percutaneous coronary intervention (PCI).
methodsAn electronic search of Medline, EMBASE, and Cochrane databases was performed through January 2024 for RCTs comparing limus DCBs vs paclitaxel DCBs for PCI. The primary endpoint was clinically driven target lesion revascularization (TLR). The secondary endpoints were late angiographic findings. Summary estimates were constructed using a random effects model.
resultsSix RCTs with 821 patients were included; 446 patients received a limus DCB, and 375 patients received a paclitaxel DCB. There was no difference between limus DCBs and paclitaxel DCBs in the incidence of TLR at a mean of 13.4 months (10.3% vs 7.8%; risk ratio [RR]: 1.32; 95% CI: 0.84-2.08). Subgroup analysis suggested no significant interaction among studies for de novo coronary lesions vs in-stent restenosis (P
conclusionsAmong patients undergoing DCB-only PCI, there were no differences in the risk of clinically driven TLR and other clinical outcomes between limus DCBs and paclitaxel DCBs. However, paclitaxel DCBs were associated with better late angiographic outcomes. These findings support the need for future trials to establish the role of new-generation limus DCBs for PCI.
Indexed as
Identifiers
38986653What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.